PYY-Dependent Restoration of Impaired Insulin and Glucagon Secretion in Type 2 Diabetes following Roux-En-Y Gastric Bypass Surgery
Reshma D Ramracheya, Laura J McCulloch, Anne Clark, David Wiggins, Helene Johannessen, Magnus Kringstad Olsen, Xing Cai, Chun-Mei Zhao, Duan Chen, Patrik Rorsman, Reshma D Ramracheya, Laura J McCulloch, Anne Clark, David Wiggins, Helene Johannessen, Magnus Kringstad Olsen, Xing Cai, Chun-Mei Zhao, Duan Chen, Patrik Rorsman
Abstract
Roux-en-Y gastric bypass (RYGB) is a weight-reduction procedure resulting in rapid resolution of type 2 diabetes (T2D). The role of pancreatic islet function in this restoration of normoglycemia has not been fully elucidated. Using the diabetic Goto-Kakizaki (GK) rat model, we demonstrate that RYGB restores normal glucose regulation of glucagon and insulin secretion and normalizes islet morphology. Culture of isolated islets with serum from RYGB animals mimicked these effects, implicating a humoral factor. These latter effects were reversed following neutralization of the gut hormone peptide tyrosine tyrosine (PYY) but persisted in the presence of a glucagon-like peptide-1 (GLP-1) receptor antagonist. The effects of RYGB on secretion were replicated by chronic exposure of diabetic rat islets to PYY in vitro. These findings indicate that the mechanism underlying T2D remission may be mediated by PYY and suggest that drugs promoting PYY release or action may restore pancreatic islet function in T2D.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.
Figures
References
- Adrian T.E., Ferri G.L., Bacarese-Hamilton A.J., Fuessl H.S., Polak J.M., Bloom S.R. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology. 1985;89:1070–1077.
- Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., Ghatei M.A., Bloom S.R. Inhibition of food intake in obese subjects by peptide YY3-36. N. Engl. J. Med. 2003;349:941–948.
- Buchwald H., Avidor Y., Braunwald E., Jensen M.D., Pories W., Fahrbach K., Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–1737.
- Cerf M.E. Transcription factors regulating beta-cell function. Eur. J. Endocrinol. 2006;155:671–679.
- Chan J.L., Mun E.C., Stoyneva V., Mantzoros C.S., Goldfine A.B. Peptide YY levels are elevated after gastric bypass surgery. Obesity (Silver Spring) 2006;14:194–198.
- Chandarana K., Gelegen C., Irvine E.E., Choudhury A.I., Amouyal C., Andreelli F., Withers D.J., Batterham R.L. Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance. Mol. Metab. 2013;2:142–152.
- Chimerel C., Emery E., Summers D.K., Keyser U., Gribble F.M., Reimann F. Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep. 2014;9:1202–1208.
- Clements R.H., Gonzalez Q.H., Long C.I., Wittert G., Laws H.L. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am. Surg. 2004;70:1–4. discussion 4–5.
- Höög A., Hu W., Abdel-Halim S.M., Falkmer S., Qing L., Grimelius L. Ultrastructural localization of insulin-like growth factor-2 (IGF-2) to the secretory granules of insulin cells: a study in normal and diabetic (GK) rats. Ultrastruct. Pathol. 1997;21:457–466.
- Jørgensen N.B., Dirksen C., Bojsen-Møller K.N., Jacobsen S.H., Worm D., Hansen D.L., Kristiansen V.B., Naver L., Madsbad S., Holst J.J. Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes. 2013;62:3044–3052.
- Kodama Y., Johannessen H., Furnes M.W., Zhao C.M., Johnsen G., Mårvik R., Kulseng B., Chen D. Mechanistic comparison between gastric bypass vs. duodenal switch with sleeve gastrectomy in rat models. PLoS ONE. 2013;8:e72896.
- Lake S.P., Bassett P.D., Larkins A., Revell J., Walczak K., Chamberlain J., Rumford G.M., London N.J., Veitch P.S., Bell P.R. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes. 1989;38(Suppl 1):143–145.
- Lee Y., Berglund E.D., Wang M.Y., Fu X., Yu X., Charron M.J., Burgess S.C., Unger R.H. Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proc. Natl. Acad. Sci. USA. 2012;109:14972–14976.
- Lindqvist A., Spégel P., Ekelund M., Mulder H., Groop L., Hedenbro J., Wierup N. Effects of ingestion routes on hormonal and metabolic profiles in gastric-bypassed humans. J. Clin. Endocrinol. Metab. 2013;98:E856–E861.
- Marchetti P., Lupi R., Bugliani M., Kirkpatrick C.L., Sebastiani G., Grieco F.A., Del Guerra S., D’Aleo V., Piro S., Marselli L. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia. 2012;55:3262–3272.
- Mokadem M., Zechner J.F., Margolskee R.F., Drucker D.J., Aguirre V. Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency. Mol. Metab. 2014;3:191–201.
- Persaud S.J., Bewick G.A. Peptide YY: more than just an appetite regulator. Diabetologia. 2014;57:1762–1769.
- Pittner R.A., Moore C.X., Bhavsar S.P., Gedulin B.R., Smith P.A., Jodka C.M., Parkes D.G., Paterniti J.R., Srivastava V.P., Young A.A. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int. J. Obes. Relat. Metab. Disord. 2004;28:963–971.
- Pournaras D.J., Osborne A., Hawkins S.C., Vincent R.P., Mahon D., Ewings P., Ghatei M.A., Bloom S.R., Welbourn R., le Roux C.W. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann. Surg. 2010;252:966–971.
- Ramracheya R., Ward C., Shigeto M., Walker J.N., Amisten S., Zhang Q., Johnson P.R., Rorsman P., Braun M. Membrane potential-dependent inactivation of voltage-gated ion channels in alpha-cells inhibits glucagon secretion from human islets. Diabetes. 2010;59:2198–2208.
- Salehi M., Prigeon R.L., D’Alessio D.A. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes. 2011;60:2308–2314.
- Sam A.H., Gunner D.J., King A., Persaud S.J., Brooks L., Hostomska K., Ford H.E., Liu B., Ghatei M.A., Bloom S.R., Bewick G.A. Selective ablation of peptide YY cells in adult mice reveals their role in beta cell survival. Gastroenterology. 2012;143:459–468.
- Shin A.C., Zheng H., Townsend R.L., Sigalet D.L., Berthoud H.R. Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery. Endocrinology. 2010;151:1588–1597.
- Tan T.M., Salem V., Troke R.C., Alsafi A., Field B.C., De Silva A., Misra S., Baynes K.C., Donaldson M., Minnion J. Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose. J. Clin. Endocrinol. Metab. 2014;99:E2317–E2324.
- Tremaroli V., Karlsson F., Werling M., Ståhlman M., Kovatcheva-Datchary P., Olbers T., Fändriks L., le Roux C.W., Nielsen J., Bäckhed F. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab. 2015;22:228–238.
- Unger R.H., Cherrington A.D. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Invest. 2012;122:4–12.
- Ye J., Hao Z., Mumphrey M.B., Townsend R.L., Patterson L.M., Stylopoulos N., Münzberg H., Morrison C.D., Drucker D.J., Berthoud H.R. GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2014;306:R352–R362.
- Zhang Q., Ramracheya R., Lahmann C., Tarasov A., Bengtsson M., Braha O., Braun M., Brereton M., Collins S., Galvanovskis J. Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. Cell Metab. 2013;18:871–882.
Source: PubMed